BIOCON
|
BIOCON Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 2.38 | 8.44 | 8.52 | 3.85 | 5.40 |
| CEPS(Rs) | 14.35 | 25.96 | 23.88 | 14.63 | 13.21 |
| DPS(Rs) | 0.50 | 0.50 | 0.50 | 1.50 | 0.50 |
| Book NAV/Share(Rs) | 206.76 | 176.73 | 162.11 | 146.53 | 68.53 |
| Tax Rate(%) | 17.66 | 24.23 | 14.91 | 28.32 | 21.51 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.62 | 19.68 | 21.41 | 18.80 | 18.18 |
| EBIT Margin(%) | 8.44 | 18.15 | 16.74 | 11.67 | 12.80 |
| Pre Tax Margin(%) | 2.63 | 12.30 | 10.22 | 7.96 | 11.98 |
| PAT Margin (%) | 2.17 | 9.32 | 8.69 | 5.70 | 9.40 |
| Cash Profit Margin (%) | 13.65 | 20.32 | 19.20 | 15.57 | 19.32 |
| Performance Ratios | |||||
| ROA(%) | 0.61 | 2.50 | 2.41 | 1.79 | 4.03 |
| ROE(%) | 1.35 | 7.03 | 7.00 | 4.98 | 9.83 |
| ROCE(%) | 3.26 | 7.43 | 7.03 | 5.37 | 8.30 |
| Asset Turnover(x) | 0.28 | 0.27 | 0.28 | 0.31 | 0.43 |
| Sales/Fixed Asset(x) | 0.38 | 0.39 | 0.41 | 0.48 | 0.77 |
| Working Capital/Sales(x) | 5.47 | 7.86 | -83.12 | 2.95 | 1.80 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 2.61 | 2.57 | 2.45 | 2.06 | 1.31 |
| Receivable days | 122.96 | 139.43 | 119.85 | 91.14 | 79.49 |
| Inventory Days | 118.06 | 117.49 | 112.31 | 105.87 | 92.60 |
| Payable days | 427.20 | 450.17 | 376.86 | 271.55 | 209.62 |
| Valuation Parameters | |||||
| PER(x) | 151.69 | 40.43 | 31.01 | 53.54 | 61.95 |
| PCE(x) | 25.15 | 13.14 | 11.06 | 14.11 | 25.33 |
| Price/Book(x) | 1.75 | 1.93 | 1.63 | 1.41 | 4.88 |
| Yield(%) | 0.14 | 0.15 | 0.19 | 0.73 | 0.15 |
| EV/Net Sales(x) | 4.14 | 3.58 | 3.06 | 3.59 | 5.29 |
| EV/Core EBITDA(x) | 18.46 | 12.48 | 10.85 | 13.90 | 19.85 |
| EV/EBIT(x) | 48.76 | 19.61 | 18.07 | 30.50 | 41.23 |
| EV/CE(x) | 1.44 | 1.39 | 1.27 | 1.13 | 3.25 |
| M Cap / Sales | 3.46 | 2.68 | 2.15 | 2.22 | 4.91 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.91 | 3.43 | 32.05 | 36.54 | 14.57 |
| Core EBITDA Growth(%) | -13.18 | 5.05 | 44.21 | 32.28 | 14.45 |
| EBIT Growth(%) | -48.34 | 11.38 | 89.92 | 25.26 | -6.64 |
| PAT Growth(%) | -74.20 | 10.14 | 101.84 | -16.67 | -8.82 |
| EPS Growth(%) | -71.81 | -0.90 | 120.99 | -28.64 | -12.48 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.44 | 0.84 | 0.81 | 1.01 | 0.60 |
| Current Ratio(x) | 1.22 | 1.14 | 0.99 | 1.45 | 2.19 |
| Quick Ratio(x) | 0.79 | 0.79 | 0.67 | 0.95 | 1.59 |
| Interest Cover(x) | 1.45 | 3.10 | 2.57 | 3.14 | 15.54 |
| Total Debt/Mcap(x) | 0.25 | 0.43 | 0.50 | 0.72 | 0.12 |
Compare Financial Ratios of peers of BIOCON
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BIOCON | ₹71,372.7 Cr | -0.6% | 3.9% | 12.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹466,179.0 Cr | -0.4% | 4.3% | 13.6% | Stock Analytics | |
| DIVIS LABORATORIES | ₹196,095.0 Cr | 0.9% | 8.9% | 8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,530.0 Cr | 0.7% | 13% | 46.5% | Stock Analytics | |
| CIPLA | ₹114,318.0 Cr | -1% | -0% | -3.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,742.1 Cr | -3.3% | -8.4% | -4.3% | Stock Analytics | |
BIOCON Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BIOCON | -0.6% |
3.9% |
12.9% |
| SENSEX | -0.6% |
-0.1% |
-6.7% |
You may also like the below Video Courses
